Zhenru Huang1, Hong Tao2, Qingdong Meng1, Long Jing1. 1. Department of Endocrinology and MetabolismBeijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Diseases, 2 Anzhen Road, Chaoyang District, Beijing 100029, ChinaBeijing Anzhen HospitalCapital Medical University, The Key Laboratory of Remodeling-Related Cardiovascular Diseases, Ministry of Education, Beijing Institute of Heart Lung and Blood Vessel Diseases, 2 Anzhen Road, Chaoyang District, Beijing 100029, China. 2. Department of Endocrinology and MetabolismBeijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Diseases, 2 Anzhen Road, Chaoyang District, Beijing 100029, ChinaBeijing Anzhen HospitalCapital Medical University, The Key Laboratory of Remodeling-Related Cardiovascular Diseases, Ministry of Education, Beijing Institute of Heart Lung and Blood Vessel Diseases, 2 Anzhen Road, Chaoyang District, Beijing 100029, China vivientao@126.com.
Abstract
OBJECTIVE: To review the published literature on the effects of telecare intervention in patients with type 2 diabetes and inadequate glycemic control. DESIGN AND METHODS: A review of randomized controlled trials on telecare intervention in patients with type 2 diabetes, and a search of electronic databases such as The Cochrane Library, PubMed, EBSCO, CINAHL, Science Direct, Journal of Telemedicine and Telecare, and China National Knowledge Infrastructure (CNKI), were conducted from December 8 to 16, 2013. Two evaluators independently selected and reviewed the eligible studies. Changes in HbA1c, fasting plasma glucose (FPG), post-prandial plasma glucose (PPG), BMI, and body weight were analyzed. RESULTS: An analysis of 18 studies with 3798 subjects revealed that telecare significantly improved the management of diabetes. Mean HbA1c values were reduced by -0.54 (95% CI, -0.75 to -0.34; P<0.05), mean FPG levels by -9.00 mg/dl (95% CI, -17.36 to -0.64; P=0.03), and mean PPG levels reduced by -52.86 mg/dl (95% CI, -77.13 to -28.58; P<0.05) when compared with the group receiving standard care. Meta-regression and subgroup analyses indicated that study location, sample size, and treatment-monitoring techniques were the sources of heterogeneity. CONCLUSIONS: Patients monitored by telecare showed significant improvement in glycemic control in type 2 diabetes when compared with those monitored by routine follow-up. Significant reduction in HbA1c levels was associated with Asian populations, small sample size, and telecare, and with those patients with baseline HbA1c greater than 8.0%.
OBJECTIVE: To review the published literature on the effects of telecare intervention in patients with type 2 diabetes and inadequate glycemic control. DESIGN AND METHODS: A review of randomized controlled trials on telecare intervention in patients with type 2 diabetes, and a search of electronic databases such as The Cochrane Library, PubMed, EBSCO, CINAHL, Science Direct, Journal of Telemedicine and Telecare, and China National Knowledge Infrastructure (CNKI), were conducted from December 8 to 16, 2013. Two evaluators independently selected and reviewed the eligible studies. Changes in HbA1c, fasting plasma glucose (FPG), post-prandial plasma glucose (PPG), BMI, and body weight were analyzed. RESULTS: An analysis of 18 studies with 3798 subjects revealed that telecare significantly improved the management of diabetes. Mean HbA1c values were reduced by -0.54 (95% CI, -0.75 to -0.34; P<0.05), mean FPG levels by -9.00 mg/dl (95% CI, -17.36 to -0.64; P=0.03), and mean PPG levels reduced by -52.86 mg/dl (95% CI, -77.13 to -28.58; P<0.05) when compared with the group receiving standard care. Meta-regression and subgroup analyses indicated that study location, sample size, and treatment-monitoring techniques were the sources of heterogeneity. CONCLUSIONS:Patients monitored by telecare showed significant improvement in glycemic control in type 2 diabetes when compared with those monitored by routine follow-up. Significant reduction in HbA1c levels was associated with Asian populations, small sample size, and telecare, and with those patients with baseline HbA1c greater than 8.0%.
Authors: G Alexander Fleming; John R Petrie; Richard M Bergenstal; Reinhard W Holl; Anne L Peters; Lutz Heinemann Journal: Diabetologia Date: 2020-02 Impact factor: 10.122
Authors: Peter Hanlon; Luke Daines; Christine Campbell; Brian McKinstry; David Weller; Hilary Pinnock Journal: J Med Internet Res Date: 2017-05-17 Impact factor: 5.428
Authors: Michelle M Alvarado; Hye-Chung Kum; Karla Gonzalez Coronado; Margaret J Foster; Pearl Ortega; Mark A Lawley Journal: J Med Internet Res Date: 2017-02-13 Impact factor: 5.428
Authors: Domingo Orozco-Beltran; Manuel Sánchez-Molla; Julio Jesus Sanchez; José Joaquin Mira Journal: J Med Internet Res Date: 2017-12-15 Impact factor: 5.428